NRIX
HEALTHCARENurix Therapeutics Inc
AI Insight
What's Moving NRIX Today?
No stock-specific AI insight has been generated for NRIX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.20$22.50
$19.72
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-61.4%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding103.4M
NRIX News
26 articles- Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst TargetYahoo Finance·Jun 16, 2026
- Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)Yahoo Finance·Jun 16, 2026
- Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Jun 15, 2026
- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of TherapyInvesting News Network·Jun 11, 2026
- TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?Yahoo Finance·Jun 11, 2026
- Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?Yahoo Finance·Jun 9, 2026
- Company News for Jun 9, 2026Yahoo Finance·Jun 9, 2026
- Broader Market Settles Higher as Chipmakers RallyBarchart·Jun 8, 2026
- Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock FlyingYahoo Finance·Jun 8, 2026
- Roche's $2.3 Billion Nurix Deal Sends Shares MovingYahoo Finance·Jun 8, 2026
- Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 BillionWall Street Journal·Jun 8, 2026
- Stocks Rally as Buyers Return After AI-Led SelloffBarchart·Jun 8, 2026
- This Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer DrugYahoo Finance·Jun 8, 2026
- Stocks Push Higher as Chipmakers and AI Companies ReboundBarchart·Jun 8, 2026
- Roche stakes $700M on Nurix’s protein-degrading drugBiopharmadive·Jun 8, 2026
- Roche and Nurix strike $2.3 billion blood cancer drug dealQz·Jun 8, 2026
- Roche signs $2.3bn blood cancer drug agreement with Nurix TherapeuticsPharmaceutical-technology·Jun 8, 2026
- NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B MarketStocktwits·Jun 8, 2026
- Nurix Therapeutics and Roche Announce Strategic Collaboration to Develop Bexobrutideg for B-Cell Malignancies and BeyondQuiver Quantitative·Jun 8, 2026
- Cancer fight: Roche agrees $700M upfront for BTK degrader bexobrutidegStock Titan·Jun 8, 2026
- Roche teams with Nurix on pill for blood cancers, MS and hives in $2.3B pactStock Titan·Jun 8, 2026
- Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyYahoo Finance Singapore·Jun 8, 2026
- Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyYahoo Finance·Jun 8, 2026
- Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushionAD HOC NEWS·May 8, 2026
- Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsightGlobeNewswire Inc.·Apr 21, 2026
- Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire Inc.·Apr 8, 2026
All 26 articles loaded
Price Data
Open$18.99
Previous Close$18.86
Day High$19.91
Day Low$18.92
52 Week High$22.50
52 Week Low$8.20
52-Week Range
$8.20$22.50
$19.72
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-61.4%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding103.4M
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—